ARDX stock icon

Ardelyx
ARDX

$5.82
5.94%
 

About: Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Employees: 267

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 10 analysts
0
News positive %
of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 28

21% more capital invested

Capital invested by funds: $849M [Q4 2023] → $1.03B (+$181M) [Q1 2024]

13% more funds holding

Funds holding: 159 [Q4 2023] → 180 (+21) [Q1 2024]

1.64% more ownership

Funds ownership: 59.0% [Q4 2023] → 60.63% (+1.64%) [Q1 2024]

9% more call options, than puts

Call options by funds: $22.8M | Put options by funds: $21M

2% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 56

50% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 2 (-2) [Q1 2024]

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$10
72%
upside
Avg. target
$13.80
137%
upside
High target
$15
158%
upside

10 analyst ratings

10 positive
100%
neutral
0%
negative
0%
Citigroup
Yigal Nochomovitz
72%upside
$10
Buy
Maintained
3 Jul 2024
Piper Sandler
Christopher Raymond
158%upside
$15
Overweight
Maintained
24 May 2024
Wedbush
Laura Chico
158%upside
$15
Outperform
Reiterated
24 May 2024
Citigroup
Yigal Nochomovitz
141%upside
$14
Buy
Maintained
3 May 2024
Wedbush
Laura Chico
158%upside
$15
Outperform
Maintained
3 May 2024

Financial journalist opinion

Based on 5 articles about ARDX published over the past 30 days